2014
DOI: 10.1111/psyg.12078
|View full text |Cite
|
Sign up to set email alerts
|

Depression in Parkinson's disease: the effectiveness and risk of pharmacotherapy. Clinical review

Abstract: Parkinson's disease (PD) is a neurological disease with a heterogeneous pattern of neurological symptoms and concomitant psychiatric syndromes. These syndromes are triggered by alterations to neurotransmission that are likely common for both neurological and psychiatric symptoms. Syndromes such as depression, anxiety, or cognitive impairment can precede motor symptoms of PD and delay its diagnosis. Recently, questions related to aetiological factors and treatment strategies of depression in PD have become a gr… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

0
7
0

Year Published

2015
2015
2022
2022

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 9 publications
(7 citation statements)
references
References 58 publications
0
7
0
Order By: Relevance
“…Despite the high prevalence of depression in PD, only 10-20% of sufferers receive treatment, which is typically anti-depressant treatment and may have limited efficacy for PD patients (Dyduch and Załuska, 2015;Frisina et al, 2008). In a meta-analysis that included randomized placebo controlled treatments for depression and anxiety in PD, we found a non-significant moderate effect size for anti-depressants (d = .71) and a significant large effect size (d = 1.57) for cognitive behaviour therapy (CBT) (Troeung et al, 2013).…”
Section: Introductionmentioning
confidence: 99%
“…Despite the high prevalence of depression in PD, only 10-20% of sufferers receive treatment, which is typically anti-depressant treatment and may have limited efficacy for PD patients (Dyduch and Załuska, 2015;Frisina et al, 2008). In a meta-analysis that included randomized placebo controlled treatments for depression and anxiety in PD, we found a non-significant moderate effect size for anti-depressants (d = .71) and a significant large effect size (d = 1.57) for cognitive behaviour therapy (CBT) (Troeung et al, 2013).…”
Section: Introductionmentioning
confidence: 99%
“…There are four core symptoms in PD: tremor at rest, rigidity, bradykinesia (slowness), and postural instability. However, more of other motor-symptoms, such as freezing and dyskinesia also observed among PwP at different stages of the disease (Dyduch & Załuska, 2014;Jankovic, 2008;Lim, Fox, & Lang, 2009;Politis, Wu, Mollis, Bain, Chaudhuri & Piccini, 2010). The non-motor symptoms are such as constipation, pain, sleep disorders, cognitive impairments, poor memory, slowness in psychological responses, problems of visuospatial functioning (Aarsland, Larsen, Karlsen, Lim, & Tandberg, 1999;Jenkinson, Peto, Fitzpatrick, Greenhall, & Hyman, 1995;Meireles & Massano, 2012;Pagonabarraga, Kulisevsky, Strafella, & Krack, 2015), and sensory motor integration impairments (Clark, Adams, Dykstra, Moodie, & Jog, 2014;Jankovic, 2008;Ramig, Fox, & Sapir, 2007;Richardson, Sussman, Stathopoulos, & Huber, 2014).…”
Section: Introductionmentioning
confidence: 97%
“…Depression is often emphasized as a major factor in determining the quality of life. However, despite its impact, there was very limited attention being paid to this matter, nor was it being treated in clinical practice (Chung et al, 2003;Dyduch & Załuska, 2014;Rahman et al, 2008;Shulman et al, 2002).…”
Section: Introductionmentioning
confidence: 99%
“…Non-motor problems co-exist with the motor dysfunction, and can be manifested intricately in many different ways. So it is an important factor to determine the quality of life which can modify the course of PD (Dyduch & Załuska, 2014).…”
Section: Introductionmentioning
confidence: 99%